{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T12:15:21Z","timestamp":1791980121243,"version":"4.4.0"},"reference-count":33,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Psychiatry"],"published-print":{"date-parts":[[2022,8,1]]},"DOI":"10.1001\/jamapsychiatry.2022.1717","type":"journal-article","created":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T15:02:09Z","timestamp":1657119729000},"page":"760","source":"Crossref","is-referenced-by-count":48,"title":["Balovaptan vs Placebo for Social Communication in Childhood Autism Spectrum Disorder"],"prefix":"10.1001","volume":"79","author":[{"given":"Eric","family":"Hollander","sequence":"first","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Albert Einstein College of Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suma","family":"Jacob","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, University of Minnesota, Minneapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Jou","sequence":"additional","affiliation":[{"name":"Child Study Center, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"McNamara","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University Hospitals, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linmarie","family":"Sikich","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell","family":"Tobe","sequence":"additional","affiliation":[{"name":"Nathan Kline Institute for Psychiatric Research, Orangeburg, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice","family":"Smith","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd, Welwyn Garden City, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Sanders","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd, Genentech, South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Squassante","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorraine","family":"Murtagh","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Gleissl","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Wandel","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Veenstra-VanderWeele","sequence":"additional","affiliation":[{"name":"Columbia University and New York State Psychiatric Institute, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"key":"yoi220038r1","doi-asserted-by":"publisher","first-page":"S55","DOI":"10.21037\/tp","article-title":"Autism spectrum disorder: definition, epidemiology, causes, and clinical evaluation.","volume":"9","author":"Hodges","year":"2020","journal-title":"Transl Pediatr"},{"issue":"4","key":"yoi220038r3","doi-asserted-by":"publisher","first-page":"658","DOI":"10.3390\/ijerph16040658","article-title":"Environmental and genetic factors in autism spectrum disorders: special emphasis on data from Arabian studies.","volume":"16","author":"Almandil","year":"2019","journal-title":"Int J Environ Res Public Health"},{"issue":"6","key":"yoi220038r4","first-page":"389","article-title":"Pharmacological therapies for autism spectrum disorder: a review.","volume":"40","author":"LeClerc","year":"2015","journal-title":"P T"},{"issue":"1","key":"yoi220038r5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/0269881117741766","article-title":"Autism spectrum disorder: consensus guidelines on assessment, treatment and research from the British Association for Psychopharmacology.","volume":"32","author":"Howes","year":"2018","journal-title":"J Psychopharmacol"},{"issue":"1","key":"yoi220038r6","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.neuron.2012.09.025","article-title":"Neuromodulation by oxytocin and vasopressin.","volume":"76","author":"Stoop","year":"2012","journal-title":"Neuron"},{"issue":"491","key":"yoi220038r8","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau7356","article-title":"A randomized placebo-controlled pilot trial shows that intranasal vasopressin improves social deficits in children with autism.","volume":"11","author":"Parker","year":"2019","journal-title":"Sci Transl Med"},{"issue":"4","key":"yoi220038r9","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1021\/acs.jmedchem.9b01478","article-title":"Discovery of balovaptan, a vasopressin 1a receptor antagonist for the treatment of autism spectrum disorder.","volume":"63","author":"Schnider","year":"2020","journal-title":"J Med Chem"},{"issue":"5","key":"yoi220038r10","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1021\/jm501745f","article-title":"Discovery of highly selective brain-penetrant vasopressin 1a antagonists for the potential treatment of autism via a chemogenomic and scaffold hopping approach.","volume":"58","author":"Ratni","year":"2015","journal-title":"J Med Chem"},{"issue":"11","key":"yoi220038r11","doi-asserted-by":"publisher","first-page":"4720","DOI":"10.1007\/s12325-020-01491-y","article-title":"Open-label assessment of the effects of itraconazole and rifampicin on balovaptan pharmacokinetics in healthy volunteers.","volume":"37","author":"Derks","year":"2020","journal-title":"Adv Ther"},{"issue":"5","key":"yoi220038r12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0037313","article-title":"Gestational valproate alters BOLD activation in response to complex social and primary sensory stimuli.","volume":"7","author":"Felix-Ortiz","year":"2012","journal-title":"PLoS One"},{"issue":"9","key":"yoi220038r13","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1038\/npp.2016.232","article-title":"A single dose, randomized, controlled proof-of-mechanism study of a novel vasopressin 1a receptor antagonist (RG7713) in high-functioning adults with autism spectrum disorder.","volume":"42","author":"Umbricht","year":"2017","journal-title":"Neuropsychopharmacology"},{"issue":"8","key":"yoi220038r16","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1080\/13543784.2021.1948009","article-title":"Bioavailability and pharmacokinetic profile of balovaptan, a selective, brain-penetrant vasopressin 1a receptor antagonist, in healthy volunteers.","volume":"30","author":"Derks","year":"2021","journal-title":"Expert Opin Investig Drugs"},{"issue":"491","key":"yoi220038r18","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aat7838","article-title":"A phase 2 clinical trial of a vasopressin V1a receptor antagonist shows improved adaptive behaviors in men with autism spectrum disorder.","volume":"11","author":"Bolognani","year":"2019","journal-title":"Sci Transl Med"},{"issue":"12","key":"yoi220038r19","doi-asserted-by":"publisher","first-page":"4258","DOI":"10.1007\/s10803-020-04494-4","article-title":"National and state estimates of adults with autism spectrum disorder.","volume":"50","author":"Dietz","year":"2020","journal-title":"J Autism Dev Disord"},{"issue":"11","key":"yoi220038r20","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1001\/jamapediatrics.2013.2698","article-title":"Baseline factors predicting placebo response to treatment in children and adolescents with autism spectrum disorders: a multisite randomized clinical trial.","volume":"167","author":"King","year":"2013","journal-title":"JAMA Pediatr"},{"issue":"11","key":"yoi220038r21","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.1007\/s10803-013-1798-7","article-title":"Measurement tools and target symptoms\/skills used to assess treatment response for individuals with autism spectrum disorder.","volume":"43","author":"Bolte","year":"2013","journal-title":"J Autism Dev Disord"},{"issue":"41","key":"yoi220038r22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta19410","article-title":"Systematic review of tools to measure outcomes for young children with autism spectrum disorder.","volume":"19","author":"McConachie","year":"2015","journal-title":"Health Technol Assess"},{"issue":"5","key":"yoi220038r23","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1177\/1362361314542955","article-title":"Measuring social communication behaviors as a treatment endpoint in individuals with autism spectrum disorder.","volume":"19","author":"Anagnostou","year":"2015","journal-title":"Autism"},{"issue":"1","key":"yoi220038r24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0924-9338(12)74807-1","article-title":"P-640\u2014the power of expectation bias.","volume":"27","author":"Williams","year":"2012","journal-title":"Eur Psychiatry"},{"issue":"1","key":"yoi220038r25","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1176\/appi.ajp.2008.08020247","article-title":"Placebo response in randomized controlled trials of antidepressants for pediatric major depressive disorder.","volume":"166","author":"Bridge","year":"2009","journal-title":"Am J Psychiatry"},{"issue":"1","key":"yoi220038r26","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13229-020-00372-z","article-title":"Placebo response in pharmacological and dietary supplement trials of autism spectrum disorder (ASD): systematic review and meta-regression analysis.","volume":"11","author":"Siafis","year":"2020","journal-title":"Mol Autism"},{"issue":"3","key":"yoi220038r27","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/S2215-0366(21)00429-6","article-title":"Efficacy and safety of balovaptan for socialisation and communication difficulties in autistic adults in North America and Europe: a phase 3, randomised, placebo-controlled trial.","volume":"9","author":"Jacob","year":"2022","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"yoi220038r28","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/2040-2392-2-3","article-title":"Functionality of promoter microsatellites of arginine vasopressin receptor 1A (AVPR1A): implications for autism.","volume":"2","author":"Tansey","year":"2011","journal-title":"Mol Autism"},{"issue":"7","key":"yoi220038r29","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1038\/npp.2016.237","article-title":"Arbaclofen in children and adolescents with autism spectrum disorder: a randomized, controlled, phase 2 trial.","volume":"42","author":"Veenstra-VanderWeele","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"yoi220038r30","doi-asserted-by":"publisher","DOI":"10.1211\/PJ.2017.20203390","article-title":"Pharmacologic treatment options for children and adolescents with autism spectrum disorder.","author":"Fosdick","journal-title":"Pharma J"},{"issue":"2","key":"yoi220038r31","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1097\/WCO.0000000000000542","article-title":"Clinical trials in autism spectrum disorder: evidence, challenges and future directions.","volume":"31","author":"Anagnostou","year":"2018","journal-title":"Curr Opin Neurol"},{"key":"yoi220038r32","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jpeds.2016.06.004","article-title":"To screen or not to screen universally for autism is not the question: why the task force got it wrong.","volume":"176","author":"Pierce","year":"2016","journal-title":"J Pediatr"},{"issue":"4","key":"yoi220038r33","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.chc.2008.06.011","article-title":"Interventions to improve communication in autism.","volume":"17","author":"Paul","year":"2008","journal-title":"Child Adolesc Psychiatr Clin N Am"},{"key":"yoi220038r2","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2013","edition":"5th ed"},{"key":"yoi220038r7","author":"Grundschober","year":"2018"},{"key":"yoi220038r14","unstructured":"A study investigating the absolute oral bioavailability of balovaptan after single and multiple daily oral doses of balovaptan in healthy volunteers. ClinicalTrials.gov identifer: NCT03764449. Updated February 24, 2020. Accessed June 20, 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03764449"},{"key":"yoi220038r15","unstructured":"A study of RO5285119 in healthy volunteers. ClinicalTrials.gov identifer: NCT01418963. Updated November 2, 2016. Accessed June 20, 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01418963"},{"key":"yoi220038r17","unstructured":"A study of RG7314 to investigate efficacy and safety in individuals with autism spectrum disorders (ASDs). ClinicalTrials.gov identifier: NCT01793441. Updated February 3, 2017. Accessed June 20, 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01793441"}],"container-title":["JAMA Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/articlepdf\/2793696\/jamapsychiatry_hollander_2022_oi_220038_1659381711.12916.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T15:02:44Z","timestamp":1659538964000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/fullarticle\/2793696"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2022,8,1]]},"references-count":33,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapsychiatry.2022.1717","relation":{},"ISSN":["2168-622X"],"issn-type":[{"value":"2168-622X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8,1]]}}}